- 1 To what extent do we need to rely on non-pharmaceutical interventions while
- 2 COVID-19 vaccines roll out in 2021?

8

- 4 Juan Yang<sup>1,2</sup>\*, Valentina Marziano<sup>3</sup>\*, Xiaowei Deng<sup>1</sup>, Giorgio Guzzetta<sup>3</sup>, Juanjuan
- 5 Zhang<sup>1,2</sup>, Filippo Trentini<sup>3</sup>, Jun Cai<sup>1</sup>, Piero Poletti<sup>3</sup>, Wen Zheng<sup>1</sup>, Wei Wang<sup>1</sup>, Qianhui
- 6 Wu<sup>1</sup>, Zeyao Zhao<sup>1</sup>, Kaige Dong<sup>1</sup>, Guangjie Zhong<sup>1</sup>, Cécile Viboud<sup>4</sup>, Stefano Merler<sup>3†</sup>,
- 7 Marco Ajelli<sup>5,6†</sup>, Hongjie Yu<sup>1,2,7†</sup>
- 9 1. Shanghai Institute of Infectious Disease and Biosecurity, School of Public Health,
- 10 Fudan University, Shanghai, China
- 11 2. Fudan University, Key Laboratory of Public Health Safety, Ministry of Education,
- 12 Shanghai, China
- 13 3. Center for Health Emergencies, Bruno Kessler Foundation, Trento, Italy
- 14 4. Division of International Epidemiology and Population Studies, Fogarty
- 15 International Center, National Institutes of Health, Bethesda, MD, USA
- 16 5. Department of Epidemiology and Biostatistics, Indiana University School of
- 17 Public Health, Bloomington, IN, USA
- 18 6. Laboratory for the Modeling of Biological and Socio-technical Systems,
- 19 Northeastern University, Boston, MA, USA
- 20 7. Department of infectious diseases, Huashan Hospital, Fudan University, Shanghai,
- 21 China

22

23 \*These authors contributed equally to this work.

<sup>†</sup>These authors are joint senior authors contributed equally to this work.

26 Corresponding authors: Marco Ajelli, Department of Epidemiology and Biostatistics,

27 Indiana University School of Public Health, 47405 Bloomington, IN, USA; E-mail:

28 marco.ajelli@gmail.com, and Hongjie Yu, , Shanghai Institute of Infectious Disease

and Biosecurity, School of Public Health, Fudan University, Shanghai 200032, China

30 E-mail: yhj@fudan.edu.cn

25

31

32 Word count (main text): 4,928

33 Word count (abstract): 148

Abstract

34

47

natural immunity.

35 COVID-19 vaccination is being conducted in over 190 countries/regions to control 36 SARS-CoV-2 transmission and return to a pre-pandemic lifestyle. However, 37 understanding when non-pharmaceutical interventions (NPIs) can be lifted as 38 immunity builds up remain a key question for policy makers. To address it, we built a 39 data-driven model of SARS-CoV-2 transmission for China. We estimated that to 40 prevent the escalation of local outbreaks to widespread epidemics, stringent NPIs 41 need to remain in place at least one year after the start of vaccination. Should NPIs 42 alone be capable to keep the reproduction number (R<sub>t</sub>) around 1.3, the synergetic 43 effect of NPIs and vaccination could reduce up to 99% of COVID-19 burden and 44 bring R<sub>t</sub> below the epidemic threshold in about 9 months. Maintaining strict NPIs 45 throughout 2021 is of paramount importance to reduce COVID-19 burden while 46 vaccines are distributed to the population, especially in large populations with little

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

The novel coronavirus disease 2019 (COVID-19) pandemic is far from over with cases still surging in many countries across the globe, particularly with India suffering from a catastrophic second wave <sup>1</sup>. In 2020, epidemic suppression and/or mitigation have relied on non-pharmaceutical interventions (NPIs), including social distancing, school closure, masking, and case isolation. Although effective and widely adopted to limit SARS-CoV-2 transmission and reduce COVID-19 burden, these interventions entail enormous economic costs and negatively affect quality of life <sup>2</sup>. Additionally, in many countries, relaxation of NPIs has led to a resurgence of the epidemic as herd immunity has not been reached thus far <sup>3</sup>. Effective vaccines against COVID-19 remain the only foreseeable means of both suppressing the infection and returning to pre-pandemic social and economic activity patterns. Globally, several vaccines have been licensed, and vaccination programs have been initiated in more than 190 countries/regions, including China <sup>4</sup>. However, the projected global production and delivery capacities are likely to be inadequate to provide COVID-19 vaccines to all individuals who are still susceptible to SARS-CoV-2 infection <sup>3</sup>. The effectiveness of COVID-19 vaccination campaigns will depend on several factors, including pre-existing immunity, vaccine supply, willingness to receive the vaccine, and strategies for vaccine allocation and deployment <sup>5</sup>. To avoid widespread transmission of SARS-CoV-2, since the end of the first

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

COVID-19 wave in the spring of 2020, China has implemented strict NPIs and has successfully controlled local outbreaks, preventing a second widespread wave of COVID-19. Since December 2020, China has given conditional approval for the use of four COVID-19 vaccines and emergency use approval for one. As of May 7, 2021, 308 million doses (corresponding to 10.7% of the population) have been administered <sup>6</sup>. However, such a coverage is still extremely low and thus China remains highly vulnerable to importations of SARS-CoV-2 and onward transmission, as proved by several local outbreaks that occurred in the first four months of 2021, the largest of which occurring in Heilongjiang province led to 659 reported cases and spilled over to a neighboring province (419 cases were reported in Jilin) <sup>7</sup>. At present, estimating whether and when NPIs can be lifted, and the extent to which we need to rely on NPIs while vaccines roll out represents a top priority for policy making. This question has not been well addressed in China, one of the few countries in the world where nearly the entire population is still susceptible to SARS-CoV-2 infection, and home to almost 1.4 billion individuals (roughly 18% of the world population). To fill this gap, we built on top of the wide body of work adopting mathematical models of the infection transmission process to evaluate vaccination programs <sup>8-12</sup>. In particular, we developed an age-structured stochastic model to simulate SARS-CoV-2 transmission triggered by cases imported in mainland China, based on a susceptible-infectious-removed (SIR) scheme (Supplementary Fig.1). We consider a situation in which: i) no ongoing widespread SARS-CoV-2 transmission, ii) nearly no

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

immunity in the population, and iii) high risk of importing SARS-CoV-2 infected individuals, possibly leading to an upsurge of COVID-19 cases. Since COVID-19 vaccines are expected to continue rolling out throughout 2021-2022, we consider also alternative scenarios where SARS-CoV-2 infections leading to an outbreak are imported when 10% (close to the coverage as of May 2021), 20%, and 30% of the Chinese population has already been vaccinated (according to the simulated vaccination program). In the model, we account for heterogeneous mixing patterns by age <sup>13</sup> and progressive vaccine deployment among different population segments based on a priority scheme (essential workers, older adults and individuals with underlying conditions, etc.) <sup>14</sup>. Further, we overlay a disease burden model on the transmission model to estimate the number of symptomatic cases, hospitalizations, ICU admissions, and deaths under different vaccination scenarios and based on empirical data <sup>15-20</sup>. The resulting integrated model is informed by data on COVID-19 natural history, age-mixing patterns specific to China quantified during the pre-pandemic period, and the size of the different vaccination targets in the Chinese population (e.g., individuals with pre-existing conditions). A qualitative model description is reported in the Methods section, a summary of model parameters and data sources is reported in Supplementary Table 1, all other details are reported in Supplementary File 1-5. The combined effect of NPIs and vaccination programs are evaluated in terms of their ability in reducing the disease burden caused by outbreaks arising from possible

importation of cases.

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

We considered a baseline vaccination scenario where: 1) vaccination starts 15 days after an outbreak triggered by 40 breakthrough imported SARS-CoV-2 infections; 2) vaccine efficacy (VE) against SARS-CoV-2 infections for a two-dose schedule (with a 21-day interval) is set at 80% <sup>21</sup>; 3) vaccination coverage is capped at 70% across all ages <sup>14</sup>; 4) 6 million doses are administered daily (4 per 1,000 individuals, informed by the ongoing COVID-19 vaccination program <sup>6</sup>, and estimates of vaccine supply till 2021 in China <sup>22-26</sup>); 5) the first priority target consists of older adults and individuals with underlying conditions (descriptions in details shown in Supplementary Table 2); 6) there is no prior population immunity from natural infection, which aligns with the situation in most of China where there has been little circulation of SARS-CoV-2 as of May 2021  $^3$ ; 7) we assume an initial reproductive number  $R_t = 2.5$  at the start of the outbreak <sup>27-32</sup>, in the absence of NPIs and vaccination; 8) Children under 15 years of age were considered to have a lower susceptibility to SARS-CoV-2 infection as compared to adults (i.e., individuals aged 15 to 64 years), while individuals aged 65+ years had the highest susceptibility to infection (Supplementary Table 1) <sup>33,34</sup>; and 9) we let the model run for two years. To evaluate the impact of the baseline assumptions on our results, we conduct comprehensive sensitivity analyses (SA).

#### Results

#### Main analysis

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

In the absence of NPIs, the vaccination program is too slow to lower and delay the epidemic (Fig. 1a) and does not effectively reduce COVID-19 burden. R<sub>t</sub> falls below the epidemic threshold (<1) 69 days after the epidemic start (Fig. 1b), but this is primarily attributable to immunity gained through natural infection rather than vaccination. Indeed, in this time frame, 52.2% of population gets infected, while only 6.7% of population has been vaccinated (Fig. 1c). The cumulative number of symptomatic cases and deaths over a 2-year period only decrease by 3.3% (95%CI, 3.1%-4.7%) and 6.7% (95%CI, 4.5%-8.9%), respectively, as compared to a reference scenario where there is no vaccination and no NPIs, which would lead to 306.73 million (95%CI, 282.68-320.60) symptomatic cases, 99.25 million (95%CI, 92.55-104.51) hospitalizations, 7.19 million (95%CI, 6.00-7.83) ICU admissions, and 9.38 million (95%CI, 7.70-10.26) deaths (Fig. 2). Provided that NPIs are in place and can keep R<sub>t</sub> at 1.3 in the absence of vaccination (moderate NPIs scenario), the vaccination program could reduce COVID-19 burden by about 99% compared to the reference no-vaccination scenario, with 5.46 million (95%CI, 2.47-13.36) symptomatic cases, 1.77 million (95%CI, 0.83-4.40) hospitalizations, 73,500 (95%CI, 7,300-152,100) ICU admissions, and 76,700 (95%CI, 8,200-165,700) deaths (Fig. 2). In this context, vaccination decreases COVID-19 burden by about 40% (Fig. 2) compared to a situation with moderate NPI alone, and R<sub>t</sub> falls below the epidemic threshold about 9 months after the epidemic start (Fig. 1). At the time that R<sub>t</sub> falls below 1, we estimate that 50.8% of the total

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

population would have been vaccinated, while 0.8% would have been naturally infected (Fig. 1g-i). This highlights that a relevant proportion of the population would be still susceptible to SARS-CoV-2 at that time. Although in the long-term vaccination can ultimately lead to the suppression of transmission, it is necessary to maintain NPIs for one year after the onset of vaccination. Indeed, if NPIs are relaxed from moderate (R<sub>t</sub>=1.3) to mild (R<sub>t</sub>=1.5) 9 months after vaccination start, the cumulative death toll could increase from 76,700 to 173,000. In contrast, a small increase in cumulative deaths from 76,700 to 81,700 is expected if this relaxation occurs one year after vaccination start, while earlier or more drastic relaxations of NPIs lead to substantial increases in deaths (Extended Data Fig.1-3). A combination of more stringent NPIs (i.e., capable of keeping  $R_t = 1.1$ ) and vaccination (vax + high NPIs scenario) could suppress the epidemic, with <2,300 symptomatic cases, and <50 deaths on average. Although the majority of the reduction of COVID-19 burden is ascribable to NPIs in this case (over 85%), the deaths averted due to vaccination are about 1.2 million (Fig. 1j-l, and Fig. 2). If we consider a set of mild NPIs (vax + mild NPIs scenario), even a relatively low initial reproduction number under NPIs of R<sub>t</sub>=1.5 could still lead to a disastrous epidemic, with nearly two million deaths. Despite the high death toll of the resulting epidemic, NPIs and vaccination would jointly reduce around 80% of the disease burden compared to a scenario with no NPIs and no vaccination (namely, 239 million

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

symptomatic cases and 8.2 million deaths averted) (Fig. 1d-f, and Fig. 2). **Vaccine distribution capacity** Should the daily vaccination rollout be limited to 1.3 million doses (1 per 1,000 individuals – a slower rate than during the 2009 H1N1 pandemic), vaccination would not effectively reduce COVID-19 related deaths unless there was adoption of stringent NPIs. In a scenario where vaccination capacity reaches 10 million doses administered per day (7 per 1,000 individuals), vaccination would reduce COVID-19 related deaths to <5,000 for moderate NPIs and <30 for high NPIs. Should the daily vaccination capacity be increased to 15 million doses (10 per 1,000 individuals), vaccination could effectively reduce deaths to <100,000 (similar to the annual influenza-related death toll in China<sup>35</sup>) even in the presence of mild NPIs. However, even if the daily vaccination capacity could be increased to 30 million doses (20 per 1,000 individuals), in the absence of NPIs, we estimate that over 7.7 million deaths would still occur (Fig. 3). Similar patterns are estimated for the number of symptomatic cases, hospitalizations and ICU admissions (Extended Data Fig.4-6). Increasing daily vaccination capacity could largely shorten the time needed to control SARS-CoV-2 transmission. For instance, when considering a daily capacity of 10 million and 15 million doses and moderate NPIs, R<sub>t</sub> would drop below 1 about 8 and 6 months respectively after epidemic onset (to be compared to the 9.3 months

estimated with the baseline capacity of 6 million doses). At that time, over 60% of the

population would be vaccinated and ≤0.1% would be naturally infected. An upscale in the daily capacity to 10 or 15 million doses would allow a relaxation of NPIs from moderate to mild already 6 to 9 months after vaccination start, i.e., 3 to 6 months earlier with respect to the baseline. On the other hand, more drastic relaxations of NPIs (e.g., from moderate to no NPIs) would still lead to substantial increases in symptomatic cases and deaths (Extended Data Fig.7-10).

## Vaccination prioritization

We consider alternative vaccination scenarios that prioritize essential workers (staff in the healthcare, law enforcement, security, community services, and individuals employed in cold chain, etc.) to maintain essential services and then explore different prioritization strategies for the rest of the population. Our results suggest that the relative timing of the epidemic and of the vaccination rollout play a key role in determining the most effective strategy. In particular if we consider vaccination to start two weeks after 40 cases are detected, there is no clear prioritization strategy that minimize deaths, as the outcome of the vaccination campaign heavily depends on the timing at which the epidemic unfolds (Fig. 4 and Extended Data Fig. 11-12). Instead, if the epidemic is already underway when the vaccination campaign starts (>5,000 cases), prioritizing working-age groups minimizes the number of deaths when  $R \le 1.3$ . In contrast, prioritizing older adults and individuals with underlying conditions is more effective when  $R \ge 1.5$  (direct benefits are higher, Fig. 4 and Extended Data Fig. 11-12). Two results are independent of the adopted prioritization strategy: i) if  $R \ge 1.5$ .

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

then an epidemic cannot be avoided; and ii) when  $R_t = 1.1$ , over 99% of deaths can be averted (Extended Data Fig. 11-12). Population immunity at the onset of an outbreak In December 2020, vaccination has started in China, while measures to detect imported cases and case surveillance are in place. The number of doses distributed per day has changed over time, following an increasing trend and with a daily average of about 6 million doses over the period April 20 – May 7, 2017 (Supplementary File 3). As of May 7, 2021, the vaccination coverage is 10.7% <sup>6</sup>. The effectiveness of the vaccination program and NPIs in preventing new COVID-19 outbreaks and limiting COVID-19 burden will thus depend on the level of vaccine-induced immunity in the population should an outbreak of locally transmitted cases start to unfold. To simulate this situation, we initialize the model by considering different fractions of vaccinated population (SAI: 10%; SA2: 20%; SA3: 30%) at the time the infection is seeded. Given a certain level of NPIs in the absence of immunity, increasing proportions of vaccinated individuals will decrease the effective reproduction number (e.g.,  $R_t = 1.1$  in the absence of immunity, corresponds to  $R_t$  below the epidemic threshold if 10% or more of the population has been vaccinated). Should 30% of the population already been vaccinated before the start of a new wave, continuing the vaccination program while adopting mild NPIs would reduce the death

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

toll by 98% (42,400 deaths as compared 1.8 million if no one was vaccinated). However, in the absence of NPIs, even if 30% of population was already vaccinated before the start of a new wave, carrying on with the vaccination program alone would not be enough to prevent a widespread epidemic leading to 6 (95%CI: 4-7) million deaths (Extended Data Fig. 13). Vaccination coverage No significant difference in willingness-to-vaccination between age groups has been reported in China <sup>36-38</sup>. Accordingly, we use a homogenous vaccine coverage of 70% among all age groups in the main analysis. Here we present the results of a set of sensitivity analyses assuming vaccination coverage of 50% (SA4) and 90% (SA5) among all age groups, and considering heterogeneous coverages by age: 1) 70% for adults  $\geq 20$  years and 50% for younger individuals (SA6); 2) 90% for adults  $\geq 20$  years and 70% for younger individuals (SA7); 3) 70% for adults  $\geq$ 20 years and no vaccination for younger individuals (SA8). By considering moderate NPIs (R<sub>t</sub>=1.3) and a vaccination coverage of 50% in all age groups, the number of symptomatic is estimated to decrease by 33% with an 8% decrease of the death toll with respect to the baseline vaccination scenario (70% coverage) (Extended Data Fig.14-15). In fact, the lower coverage in older age groups would lead to an earlier vaccination in younger age groups who are characterized by the highest contact rates <sup>13</sup>. Conversely, increasing the coverage to 90% would

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

decrease the death tolls but lead to an increase of symptomatic cases (Extended Data Fig. 14-15). It is important to remark that these results consider that moderate NPIs remain in place over the entire duration of the epidemic, and they do not provide indications of the coverage needed to suppress any further resurgences of cases. As compared to the baseline vaccination scenario (70% vaccination coverage in all age groups), if the vaccine is not distributed among individuals aged less than 20 years, we estimate an increase of the death toll of 69% and of symptomatic infections of 55% (Extended Data Fig.14-15). The scenario assuming 90% vaccination coverage for adults ≥20 years and 70% for younger individuals lead to a lower reduction of COVID-19 burden as compared with the baseline vaccination scenario (Extended Data Fig. 14-15). The higher coverage in the adult population result in a delayed start of vaccination of the young population, which is characterized by higher contacts rates <sup>13</sup>. Nonetheless, it is important to remark that this result depends on the timing of the introduction of the initial seeds (see previous section). **Vaccine efficacy** Three types of COVID-19 vaccines are currently in use in China, including inactivated, recombinant protein subunit, and adenovirus-vectored vaccines. VE for these vaccines ranges from 65% to 90%, with the exception of the one tested in Brazil where P1 variant is prevalent (VE=50%) <sup>39-43</sup>. With respect to an 80% VE adopted in the baseline scenario, by considering VE=60% (SA9) we estimate a 1.02-fold increase

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

of the death toll and 1.64-fold increase of symptomatic cases. Whereas a 37% and 29% decrease of deaths and symptomatic cases, respectively, is estimated for VE=90% (*SA10*). (Extended Data Fig.14-15) **SARS-CoV-2** variants Multiple SARS-CoV-2 variants have been documented globally, three of which are of particular concern: lineage B.1.1.7 identified in UK, B.1.351 in South Africa, and P.1 in Brazil 44. These variants are estimated to have higher transmissibility 45,46 and possibly an increased mortality <sup>47,48</sup>. To assess the effect of vaccination in this context, we consider higher values of R<sub>t</sub> (i.e., 1.7, 1.9, and 2.1 – about 30%-60% increased transmissibility with respect to the main analysis 45) to account for enhanced transmissibility, and use a mean death hazard ratio of 1.64 to account for higher mortality <sup>47</sup>. With the assumption of VE=80% against the new variant, COVID-19 burden substantially increases, compared to the scenario based on the historical lineage. The number of symptomatic cases increase from 2 thousand to 173 million, and death increase from <50 to 7 million even when strict NPIs are implemented (Extended Data Fig. 16). Alternative vaccination parameters and scenarios A further set of sensitivity analyses are conducted to evaluate the impact of baseline assumptions on our results for R<sub>1</sub>=1.3 (moderate NPIs). Provided that vaccination can only protect against illness (SA11) but not SARS-CoV-2 infections, COVID-19 related

deaths increase by 33 folds with respect to the baseline: from 76,700 to 2.66 million (Extended Data Fig. 14). In this case, maintaining stringent NPIs measures in place for a prolonged time horizon would be necessary as such vaccine would not be effective to suppress transmission (as reported in previous studies <sup>49</sup>). Assuming a shorter duration of vaccine-induced protection of 6 months (SA12) instead of a lifelong protection (i.e., longer than the 2-year time horizon considered, Extended Data Fig.14) has a similarly large effect on projections. In our main analysis, we use the contact matrix estimated from a contact survey conducted in Shanghai before the COVID-19 pandemic <sup>13</sup>. Should a new COVID-19 wave start to unfold in China, it is unclear to what extent pre-pandemic contact patterns could be representative of such a situation. Therefore, we have added a sensitivity analysis where we assume the mixing patterns estimated in Shanghai in March 2020 <sup>50</sup>, when schools were still closed as a response to the COVID-19 pandemic (SA13). For R<sub>t</sub>=1.3 and the baseline parameters for the vaccination, the estimated number of deaths would be 16,000 as compared to 76,700 estimated using the pre-pandemic mixing patterns (79% decrease, see Extended Data Fig.14). In fact, the relative contribution of the adult population (which is the main target of the vaccination campaign) to the overall transmission as compared to children is higher than when considering pre-pandemic mixing patterns (when schools were open and school-age individuals had the highest number of contacts).

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

Other factors such as excluding detected symptomatic cases from vaccination (*SA14* and *SA15*), the time interval between two doses (*SA16 and SA17*), and assuming an all-or-nothing vaccine (*SA18*), do not substantially affect estimates of deaths and symptomatic infections (Extended Data Fig.14-15). A similar trend is observed for hospitalized cases and ICU admissions.

## **Discussion**

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

Using a stochastic dynamic model of SARS-CoV-2 transmission and COVID-19 burden tailored to the epidemiological situation in China, we find that in the absence of NPIs, and independently of the vaccine prioritization strategy and capacity of the vaccination campaign, timely rollout of an effective vaccine (VE =80%) would not be enough to prevent a local outbreak to escalate to a major widespread epidemic. Provided that NPIs are in place and capable to bring R<sub>t</sub> to 1.3, a daily vaccine rollout of 4 doses per 1,000 individuals could reduce around 99% of COVID-19 burden, and bring R<sub>t</sub> below the epidemic threshold about 9 months after the start of the vaccination campaign. A relaxation of NPIs that bring the value of R<sub>t</sub> to 1.5 could not prevent sustained epidemic growth which would cause 1.8 million deaths. A net reproduction number of 1.5 could only be sustained when accompanied by an improvement of the vaccine administration capacity up to 10 doses per 1,000 individuals per day. Relaxation of NPIs in the first 6-9 months of vaccine rollout could lead to substantial increases of COVID-19 burden if daily vaccination capacity could not be enhanced to 10-15 million doses.

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

Bubar K, et al. evaluated COVID-19 vaccine prioritization strategies and found that prioritizing older adults is a robust strategy to minimize deaths across countries when  $R_t=1.5$ , while prioritization shifted to 20-49 years group when  $R_t=1.15^{51}$ . The broad scope of that multi-country analysis does not account for features of COVID-19 epidemiology and vaccination program that are unique to China. In particular, differently from most countries where natural immunity is building up after widespread epidemics, China has been able to suppress SARS-CoV-2 transmission for most of 2020. As a result, prior immunity is very low, thus calling for specifically tailored analysis. Nonetheless, our findings confirm that if NPIs can maintain transmission rates at low levels during the vaccination campaign, strategies that target indirect benefits perform better, while if transmission rates remain high, strategies maximizing direct benefits may save more lives<sup>51</sup>. As highlighted in vaccination studies in Italy<sup>52</sup>, in the race between the vaccination campaign to build population herd-immunity and the progress of the epidemic, the speed of vaccine deployment is critical. Considering the average vaccine distribution capacity of the current COVID-19 vaccination campaign in China <sup>6</sup>, we use 6 million doses administered per day in the baseline analysis. Several manufacturers state that a total of 3.9 billion doses of COVID-19 vaccine could be produced in 2021, equivalent to about 10 million doses per day <sup>22-26</sup>. China committed to provide COVID-19 vaccines to >100 countries, and thus that could reduce the number of doses to be

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

distributed locally. Even if these candidate vaccines could be licensed and manufactured smoothly, it would take about one year to vaccinate 70% of the population. Five months after initiating vaccination program, 10.7% of Chinese population has been vaccinated <sup>6</sup>. Limited vaccine production capacity, particularly at the initial stage, could slow the speed of vaccine rollout. Slower rates of vaccine production and administration may result in a longer period of SARS-CoV-2 transmission. It is thus crucial to keep monitoring local outbreaks and invest resources in outbreak management (as currently done in China) in order to keep R<sub>t</sub> close to the epidemic threshold at least for the next 1-2 years. In the very unique context of China, a value of R<sub>t</sub> of 1.3 would result in about 76,700 cumulative deaths, comparable to the annual influenza-related death toll in China<sup>35</sup>. The development of detailed logistical plans and tools to support an increased vaccination capacity as well as effective logistic (vaccine transport, storage, and continuous cold-chain monitoring) are key factors for a successful mass vaccination campaign. In the early phase of COVID-19 spread in Wuhan in 2019, before interventions were put in place,  $R_0$  was estimated to be in the range 2.0-3.5<sup>27-32</sup>. Given the knowledge of mechanisms of SARS-CoV-2 transmission, and the devastating consequences of an uncontrolled COVID-19 epidemic, the Chinese population would hold a precautious behavior (such as clean hands often, cough or sneeze in bent elbow, avoid close

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

contact with someone who is sick, etc.) even without the need to impose NPIs. As such, in our analysis simulating an epidemic triggered by imported cases, we decided to consider an initial R of 2.5, which is at the lower end of the estimated spectrum. SARS-CoV-2 variants are circulating globally and quickly became dominant in countries like the UK and Italy (lineage B.1.1.7), and South Africa (lineage B.1.351). Recently, a variant B.1.617 identified in India has raised global concern. As of May 7, 2021, Mainland China border control screenings have already identified imported cases with SARS-CoV-2 lineage B.1.1.7 and B.1.617. Our study shows that the spread of new more transmissible and/or more lethal variants could substantially decrease the net benefit of vaccination. Strict border quarantine and isolation as well as genomic surveillance will be key while vaccines roll out in China. Our analysis on the vaccine efficacy shows that if we consider VE=60%, both the number of symptomatic cases and deaths are estimated to double as compared to the baseline vaccination coverage of 80%. Given that the final composition of a nation-wide rollout will likely include a combination of vaccines with varying efficacy, monitoring vaccine effectiveness on the ground will remain a priority. Here we propose a general framework to evaluate the impact of COVID-19 vaccination programs in the absence/presence of NPIs and to explore priority target populations to minimize multiple disease outcomes. The proposed modeling

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

framework is adaptable to other country-specific contexts. However, it requires the collection of country-specific data about the epidemiological situation (e.g., landscape immunity of the local population, prevalence of infections), vaccination parameters (e.g., vaccine supply and capacity of immunization services, efficacy of different vaccines, target age groups), socio-demographic characteristics of the population (e.g., size of the priority population by age group, age-mixing patterns), and the priorities of the pandemic responses (e.g., limit the death toll, prevent infections). Our study has a number of limitations. First, we integrated the impact of NPIs through a simple reduction in the value of  $R_1$  at the beginning of the outbreak, homogeneously across age groups. However, our analysis does not suggest which combination of NPIs should be adopted to lower R<sub>t</sub> to a certain level, and how this would affect transmission rates in different age groups. Li, et al, estimated that individual NPIs, including school closure, workplace closure, and public events bans, were associated with reductions in R<sub>t</sub> of 13–24% on day 28 after their introduction <sup>53</sup>. Further studies are needed to pinpoint the specific NPIs to be adopted in parallel with the vaccination campaign and their impact on the quality of life of the population. Second, in China, vaccines have not been licensed for children, so we assume a 50% lower or equivalent VE for them compared to other adults. Although we show that variations in these rates do not substantially affect the overall effect of the vaccination campaign, further data on age-specific vaccine efficacy could help refine priority

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

groups. Our sensitivity analyses on vaccine coverage reveal the importance of extending the vaccination to the young population once the use of vaccines will be authorized for that age segment of the population. Third, we assumed that immunity after natural infections lasts more than the time horizon considered (two years). If this is not the case, waning of immunity would inflate the rate of susceptible individuals and thus require booster vaccinations. This could become an issue with the emergence of immune-escape variants, as reported in South Africa<sup>54</sup>. Given limited information at this stage, we did not consider this scenario in our analyses, but this is an important area of future research. Fourth, age-mixing patterns are key to assess the impact of vaccination as individuals of different ages are exposed to different transmission risks. In the main analysis, we assumed the mixing patterns to correspond to those estimated before the COVID-19 pandemic, indicating the goal of a return to pre-pandemic interactions. We have also performed a sensitivity analysis based on the mixing patterns estimated in China in March 2020<sup>50</sup>, after the lockdown was lifted but schools were still closed. How the population would mix in case of a new wave of COVID-19 starts to unfold in China remains to be seen. Moreover, our study is performed at a national scale and thus our estimates of the impact of vaccination should be interpreted cautiously at the local scale. In fact,

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

spatial heterogeneities within China in terms of risk of case importation, socio-demographic characteristics of the population, mixing and mobility patterns, vaccination coverage and capacity may affect our results. Enhanced vaccination efforts in conjunction with NPIs have been successfully used during the COVID-19 outbreak in Ruili city (Yunnan Province, China) in March-April, 2021. Our analysis, however, focuses on the assessment of whether and to what extent we need to rely on NPIs to prevent a COVID-19 epidemic while vaccines are rolled out. As such, our results cannot be used to guide a reactive spatially targeted strategy. To properly capture the peculiarity of that context, specific modeling tools mirroring the interventions adopted in China as a response to emerging outbreaks are needed. Finally, it would be interesting to analyze adaptive vaccination prioritizations that changes as the epidemiological situation evolves over time but that would require the development of dynamic optimization algorithms that are beyond the scope of this work <sup>55</sup>. Nonetheless, our study provides estimates of the effect of relaxing NPIs over the course of the epidemic. In conclusion, vaccination alone could substantially reduce COVID-19 burden, but in the foreseeable future may not be enough to prevent local outbreaks to escalate to major widespread epidemics due to limitation in the vaccine production and supply (particularly at the initial stage of the vaccination), as well as the capacity of

vaccination system. This is especially relevant in contexts where most of the
population is still susceptible to SARS-CoV-2 infection, as it is the case in most of
China. Maintaining NPIs (such as social distancing, testing, case isolation and contact
tracing, wearing masks, and limitation on large gatherings) throughout 2021 is
necessary to prevent the resurgence of COVID-19 epidemics until a sufficiently high
level of immunity is reached, which depends on the transmissibility of the variants
circulating at that time.

# Figure legend

495

496

497

498

499




Figure 1. Time series of symptomatic cases, effective reproductive number  $\mathbf{R}_{t}$ , and population infected and vaccinated.

a) Number of symptomatic cases over time as estimated in the no-NPIs scenario

(initial  $R_t$ =2.5) in the absence/presence of vaccination. b) Net reproduction number  $R_t$  over time, as estimated using a Bayesian framework (Supplementary File 6) from the time series of symptomatic cases in the no-NPIs scenario in the presence of vaccination. The horizontal line indicates the epidemic threshold  $R_t$ =1 and the vertical line indicates where  $R_t$  cross this threshold. Note that for the first few generations of cases,  $R_t$  shows an increasing pattern linked to the highly stochastic nature of epidemics in their initial phase when epidemics with initially larger  $R_t$  are more likely to survive  $^{56}$ . c) Absolute numbers and proportion of the Chinese population infected and vaccinated over time in the no-NPIs scenario in the presence of vaccination. The population size of China in 2020 is 1,439,324,000  $^{57}$ . d)-f): as a-c but for the mild NPIs scenario (initial  $R_t$ =1.5). g)-i): as a-c but for the moderate NPIs scenario (initial  $R_t$ =1.3); j)-l): As a-c but for the high NPIs scenario (initial  $R_t$ =1.1). Line denotes median, and shadow denotes quantiles 0.025 and 0.975.




Figure 2. Burden of COVID-19 in the main analysis.

a) Cumulative number of symptomatic cases as estimated under the different scenarios in the absence/presence of vaccination over the simulated 2-year period. No vaccination + no NPIs with R<sub>t</sub>=2.5 at the beginning of the outbreak is called *reference scenario*, described using dark brown bars. Light yellow bars indicate scenarios including vaccination and/or different levels of NPIs. b) Reduction in the cumulative number of symptomatic cases with respect to the *reference scenario*. Orange bars and black values indicate the contribution of NPIs, blue bars and black values indicate the

overall contribution of vaccination and NPIs, while the white values indicate net contribution of vaccination; c)-d) As a-b but for hospitalized cases; e)-f) As a-b but for cases admitted to ICU; g)-h) As a-b but for deaths. Number denotes median, and error bars denote quantiles 0.025 and 0.975.




Figure 3. Impact of daily vaccine administration capacity on COVID-19 deaths.

a) Cumulative number of COVID-19 deaths (millions) as estimated in the different scenarios under progressively increasing values of the daily vaccination capacity; b) Proportion of deaths averted compared to the *reference scenario*, i.e., *no vaccination* + *no NPIs* with R<sub>t</sub>=2.5 at the beginning of the outbreak. Number denotes median, and error bars denote quantiles 0.025 and 0.975.



Figure 4. Best prioritization strategy to achieve the minimal COVID-19 deaths.

Initial cases denote breakthrough COVID-19 cases, which initiates the epidemic. We consider the impact of uncertainty (i.e., "Yes" in the figure, which means 200 stochastic model realizations are performed in order to account for the ranges) in contact patterns and relative susceptibility on prioritization, and use their mean values as well (i.e., No). Baseline denotes first prioritizing older adults and individuals with

underlying conditions. Number in the box denotes the death toll (median), with t representing thousand and m representing million. Minimum denotes the lowest deaths in each scenario on the basis of median value. We compare other strategies to that with minimum deaths using rank sum test. E.g., in the context of initial cases=5,000,  $R_t$ =1.5 and using mean values of contact patterns and relative susceptibility, the baseline is the optimal strategy to minimize deaths.

547 Methods 548 SARS-CoV-2 transmission and vaccination models 549 We developed a model of SARS-CoV-2 transmission and vaccination, based on an 550 age-structured stochastic susceptible-infectious-removed (SIR) scheme, accounting for heterogeneous mixing patterns by age as estimated in Shanghai <sup>13</sup>. The Chinese 551 552 population was distributed in 18 age groups (17 5-year age groups from 0 to 84 years and one age group for individuals aged 85 years or older) <sup>57</sup>. Each age group was 553 554 further split into two subgroups: individuals with or without underlying conditions, 555 where the former was considered to be associated with an increased risk of severe outcome of COVID-19 14. 556 557 558 In the main analysis, susceptibility to SARS-CoV-2 infection was assumed to be 559 heterogeneous across ages. Children under 15 years of age were considered less 560 susceptible to infection compared to adults aged 15 to 65 years, while the older adults more susceptible <sup>33,34</sup>. Homogeneous susceptibility across age groups was explored in 561 562 sensitivity analysis (SA19). Asymptomatic and symptomatic individuals were assumed to be equally infectious <sup>33,34</sup>, and infectiousness was also assumed to be the 563 564 same across age groups <sup>33,34</sup>. 565 566 Vaccine is administered with a two-dose schedule. In the baseline model, we assumed 567 that: i) vaccination reduces susceptibility to SARS-CoV-2 infection; ii) only 568 susceptible individuals are eligible for vaccination, i.e., we excluded all individuals

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

**Vaccination scenarios** 

that have experienced SARS-CoV-2 infection; iii) duration of vaccine-induced protection lasts longer than the time horizon considered (2 years). The baseline model is schematically represented in Supplementary Fig.1 and it is described by differential systems presented in Supplementary File 1-2. Model initialization In China, the first pandemic wave of COVID-19 was controlled by intense NPIs <sup>58,59</sup>. Almost the entire population of mainland China is still susceptible to COVID-19<sup>3</sup>. As such, the model is initialized with a fully susceptible population. China has been facing mounting pressure of imported COVID-19 cases. Containment of COVID-19 has been possible only through a combination of measures such as complete- or partial-lockdown, citywide mass-screening using reverse-transcriptase-polymerase-chain-reaction (RT-PCR) testing, tracing of contacts and contacts of contacts of COVID-19 cases, which were promptly applied wherever COVID-19 transmission has popped up in mainland China <sup>60</sup>. Despite all the efforts, containment of COVID-19 appears a whack-a-mole game and sporadic outbreaks inevitably occur. Simulations are thus initialized with 40 cases, roughly corresponding to the number of cases with symptoms onset in Beijing before the detection of a local outbreak in June 11, 2020 61.

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

To explore the impact of vaccination, we ran a set of simulations in which neither NPIs nor vaccination are implemented as a reference scenario (no vax + no NPIs, i.e., effective reproductive number  $R_i=2.5$  at the beginning of simulations  $^{17,28,58}$ ), and compared it with a scenario in which vaccination only is implemented (vax + noNPIs). Further, we considered different sets of simulations in which NPIs are used to bring R<sub>t</sub> respectively down to 1.5 (mild NPIs), 1.3 (moderate NPIs), and 1.1 (high NPIs), with (vax + mild/moderate/high NPIs) or without vaccination program  $(no \ vax)$ + mild/moderate/high NPIs). In the main analysis vaccination is assumed to begin 15 days after the epidemic start. Alternative scenarios about the seeding of the epidemic were explored as sensitivity analyses. In particular, we considered the epidemic to start when 10% (SA1), 20% (SA2), and 30% (SA3) of the Chinese population has already been vaccinated. The model is run considering daily time steps. Gradual delivery of vaccine doses is implemented by vaccinating a fixed number of individuals each day. Although manufacturers state that a total of 3.9 billion doses of vaccines could be available by the end of 2021 <sup>22-26</sup>, scale-up and delivery will take months. On the basis of the 2009 H1N1 influenza pandemic vaccination program implemented in mainland China <sup>62</sup>, in the main analysis we assumed 6 million doses of COVID-19 vaccines could be administered each day (4 doses per 1,000 individuals) until uptake reaches 70% for all groups <sup>14</sup>. Different values of the daily vaccine administration capacity, i.e., 1.3 (SA20), 10 (SA21), 15 (SA22), 30 (SA23) million dose per day, are explored in

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

separate sensitivity analyses. Sensitivity analyses were also performed on the vaccination coverage which is assumed either to be homogenous  $(SA4 \text{ and } SA5)^{14}$  or heterogeneous by age (SA6, SA7, and SA8). In the main analysis, vaccination is administered to susceptible individuals only. This represents an ideal scenario where we assume that all infected individuals can be identified (e.g., either via RT-PCR while infected or via serological assays later one) and that SARS-CoV-2 infection confers a long-lasting immunity. Since infection ascertainment could be challenging and pose additional strain to the health system, we also consider two sensitivity analyses in which only detected symptomatic cases are excluded from vaccination (SA14-SA15). In the context of fast RT-PCR-based mass screening if there is an outbreak, under-ascertainment of symptomatic cases could be only related with the sensitivity of RT-PCR tests. The sensitivity is quite high (98%) if the interval between symptom onset and RT-PCR test is within 7 days, and the sensitivity decreases to 68% if the time interval is 8-14 days<sup>63</sup>. The mean time interval from symptom onset to the date of collection of the sample for PCR testing was estimated to be 4.7 days in Hunan<sup>33</sup>. Accordingly, we considered as ascertainment probabilities of symptomatic cases 70% (SA14) and 90% (SA15). Vaccination schedule and efficacy

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

There are six COVID-19 vaccines developed by China in phase 3 clinical trials, including five vaccines administered with a two-dose schedule with an interval of 14, 21, or 28 days and one single-dose recombinant adenovirus type-5-vectored vaccine. For simplicity, in the main analysis, we modeled the administration of an inactivated vaccine developed by the Beijing Institute of Biological Products, <sup>64</sup> which entail a two-dose schedule across all age groups with an interval of 21 days. In separate sensitivity analyses, we explored an interval of 14 days and 28 days (SA16-SA17). China approved its first local COVID-19 vaccine (developed by Sinopharm) for general public use on December 31, 2020, with an estimated vaccine efficacy (VE) of 79.3%. <sup>21</sup> In the main analysis, we used a VE of 80% against infection in individuals aged 20-59 years. In the developed model, vaccination confers a partial protection, i.e., vaccinated individuals are 80% less likely to develop infection upon an infectious contact. Sensitivity analyses using a VE of 60% (SA9) and 90% (SA10) were separately performed. The alternative values of VE were selected on the basis of published upper efficacy of vaccines of 94-95% and in such a way to cover a plausible efficacy range of forthcoming vaccines <sup>65-67</sup>. Phase 2 clinical trials demonstrated that vaccine immunogenicity was lower among older individuals than in younger adults <sup>64</sup>. And for other inactivated vaccines like influenza vaccine, a lower VE is observed in children compared to young adults <sup>68</sup>. Accordingly, we assumed an age-dependent VE. In particular, given a baseline

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

efficacy VE among individuals aged 20-59 years (80% in the main analysis), we assumed a 50% lower VE in individuals <20 and  $\ge$ 60 years of age (namely 40%). A scenario without age-specific variations in VE was explored as sensitivity analysis (SA24). Individuals vaccinated with the first dose could still develop infections without any immune protection, while the second dose vaccination could produce the expected vaccine efficacy after an average of 14 days. In the main analysis we assume both natural infection-induced and vaccine-induced immunity to SARS-CoV-2 infection does not wane within the considered time horizon (2 years). In additional sensitivity analyses, we considered an average duration of vaccine-induced protection of 6 months (SA12) and 1 year (SA25). We also consider a sensitivity analysis assuming that vaccination is effective in preventing symptomatic illness, but not infection (SA11), and another one assuming an all-or-nothing vaccine, i.e., the vaccine confers full protection to VE percent of vaccinated individuals (SA18). Priority order of vaccination The doses available to be distributed daily (6 million in the main analysis) are assigned by considering the following order of priority <sup>14</sup>. In the main analysis, healthcare workers are considered as the top priority (Tier 1 of the vaccination strategy); law enforcement and security workers, personnel in nursing home and social welfare institutes, community workers, workers in energy, food and

transportation sectors are included in Tier 2; adults  $\geq$  60 years of age with underlying conditions, and adults  $\geq 80$  years of age without underlying conditions, who are at the highest risk of severe/fatal COVID-19, are considered in Tier 3; individuals aged < 60 years with pre-existing medical conditions and pregnant women are included in Tier 4; individuals aged 20-59 years without underlying conditions are included in Tier 5; school-age children and younger children aged ≤5 years without underlying conditions are recommended for vaccination in Tier 6 (Supplementary File 4). Different priority orders are explored as sensitivity analyses. Healthcare workers and the other essential workers listed above are fixed in Tier 1 and Tier 2 of vaccination, while the remaining population is vaccinated as described in Supplementary Table 2 by considering different orders of prioritization only based on age and disregarding the presence of underlying conditions (SA26: first prioritization to old adults; SA27: first prioritization to working-age groups; SA28: first prioritization to school-age groups). We explore the impact of 5,000 initial cases on the prioritization strategy (SA29). To understand the impact in terms of number of infections by age, we compare the prioritization strategy when we account for the uncertainty in the contact matrix and in the susceptibility to infection by age, or not (in this context, median values of contact numbers and relative susceptibility are used).

## **COVID-19 burden model**

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

The main output of above transmission model is the age-specific number of new

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

infections per day in the subpopulation with or without underlying conditions. On top of that, we developed a model of COVID-19 disease burden to estimate the number of symptomatic cases, hospitalization, ICU admissions, and deaths in different scenarios in the presence/absence of vaccination. We computed the age-specific number of symptomatic infections in individuals with and without underlying conditions on a daily-basis, by applying an age-specific probability of respiratory symptoms, which is 18.1%, 22.4%, 30.5%, 35.5%, and 64.6% separately for 0-19, 20-39, 40-59, 60-79, and 80+ years of age, as estimated from contact tracing data in Lombardy <sup>20</sup>. We assume that individuals with and without underlying conditions have the same age-specific probability of developing symptoms. The daily age-specific number of hospital admissions in the two subpopulations was computed by applying the age-specific proportion of laboratory-confirmed symptomatic cases requiring hospitalizations (Supplementary File 5), delayed by an average time of 3.8 days between symptom onset and hospitalization <sup>17</sup>. The daily age-specific number of patients admitted to ICU in the two subpopulations was computed by applying to hospitalized cases an age-specific probability of being admitted to ICU <sup>19</sup>, and distinguishing patients requiring intensive care in survivors and non-survivors. Survivors are admitted to ICU after an average time of 7 days from hospitalization. Non-survivors are admitted to ICU after an average time of 8

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744


days after hospitalization <sup>16</sup>. The daily age-specific number of deaths in the two subpopulations was computed by applying the age-specific fatality ratio among symptomatic cases (Supplementary File 5), delayed by an average time of 13.9 days between symptom onset and death <sup>18</sup>. **Data analysis** For each scenario, 200 stochastic model realizations were performed. The outcome of these simulations determined the distributions of the number of symptomatic infections, hospitalizations, ICU admissions, and deaths. 95% confidence intervals were defined as quantiles 0.025 and 0.975 of the estimated distributions. We used a Bayesian approach to estimate R<sub>t</sub> from the time series of symptomatic cases by date of symptom onset and the distribution of the serial interval <sup>17</sup>. The methods were described in Supplementary File 6 in details. **Ethics approval** All these data were in the public domain. Ethical review for the re-use of these secondary data is not required. **Reporting summary** Further information on research design is available in the Nature Research Reporting Summary linked to this paper.

## 745 Data and code availability

746 Should the manuscript be accepted, all data and codes will be provided on *GitHub*.

| References    |
|---------------|
| ixciti tiitts |

- 748 1. Johns Hopkins University Coronavirus Research Center. New cases of COVID-19 in
- 749 world. https://coronavirus.jhu.edu/data/new-cases (2021).
- 750 2. Zhao, J. et al. Disease Burden Attributable to the First Wave of COVID-19 in China
- 751 and the Effect of Timing on the Cost-Effectiveness of Movement Restriction Policies.
- 752 *Value Health* **24**, 615-624 (2021).
- 753 3. Chen, X. et al. Serological evidence of human infection with SARS-CoV-2: a
- 754 systematic review and meta-analysis. *Lancet Glob Health* **9**, e598-e609 (2021).
- 755 4. Our World in Data. Coronavirus (COVID-19) Vaccinations.
- 756 https://ourworldindata.org/covid-vaccinations (2021).
- 757 5. Wang, W. et al. Global, regional, and national estimates of target population sizes for
- 758 covid-19 vaccination: descriptive study. *BMJ* **371**, m4704 (2020).
- 759 6. Press Conference of the Joint Prevention and Control Mechanism of the State
- 760 Council. Introduction to the promotion of COVID-19 vaccination (Up to May 7).
- 761 http://www.gov.cn/xinwen/2021-05/08/content\_5605360.htm (2021).
- 762 7. National Health Commission of the People's Republic of China. Outbreak report.
- 763 http://www.nhc.gov.cn/xcs/yqtb/list\_gzbd.shtml (2021).
- 764 8. Anderson, R.M. & May, R.M. Vaccination and herd immunity to infectious diseases.
- 765 *Nature* **318**, 323-329 (1985).
- 766 9. Agur, Z., Cojocaru, L., Mazor, G., Anderson, R.M. & Danon, Y.L. Pulse mass measles
- 767 vaccination across age cohorts. Proc Natl Acad Sci U S A 90, 11698-11702 (1993).
- 768 10. Chao, D.L., Halloran, M.E. & Longini, I.M., Jr. Vaccination strategies for epidemic



| 791   |                                   | J Med 382, 1708-1720 (2020).  |
|---|-----------------------------------|---|
| 792   | 20.                               | Poletti, P. et al. Association of Age With Likelihood of Developing Symptoms and  |
| 793   |                                   | Critical Disease Among Close Contacts Exposed to Patients With Confirmed  |
| 794   |                                   | SARS-CoV-2 Infection in Italy. JAMA Netw Open 4, e211085 (2021).  |
| 795   | 21.                               | Sinopharm. Sinopharm COVID-19 vaccine licensed in China.  |
| 796   |                                   | http://www.sinopharm.com/s/1223-3763-38840.html (2021).   |
| 797   | 22.                               | CNWest. Curret development and production capacity of domestic COVID-19 vaccine.  |
| 798   |                                   | http://news.cnwest.com/szyw/a/2020/12/04/19343015.html (2021).  |
| 799   | 23.                               | Huanqiu Net. Chairman of Cansino Bio: After the increase in production capacity, the  |
| 800   |                                   | company's COVID-19 vaccine will be released in large quantities.  |
| 801   |                                   | https://baijiahao.baidu.com/s?id=1692936657439211781𝔴=spider&for=pc (2021).   |
|   |                                   |   |
| 802   | 24.                               | Sinopharm. The first batch of BBIBP-CorV(Sinopharm) has shipped.  |
| 802<br>803                                    | 24.                               | Sinopharm. The first batch of BBIBP-CorV(Sinopharm) has shipped. <a href="http://www.sinopharm.com/s/1223-3769-39020.html">http://www.sinopharm.com/s/1223-3769-39020.html</a> (2021).  |
|   | <ul><li>24.</li><li>25.</li></ul> |   |
| 803   |                                   | http://www.sinopharm.com/s/1223-3769-39020.html (2021).   |
| 803<br>804                                    |                                   | http://www.sinopharm.com/s/1223-3769-39020.html (2021).  Reuters. Sinovac claims that the annual production capacity of COVID-19 vaccine will   |
| 803<br>804<br>805                             |                                   | http://www.sinopharm.com/s/1223-3769-39020.html (2021).  Reuters. Sinovac claims that the annual production capacity of COVID-19 vaccine will reach 2 billion doses by June.  |
| 803<br>804<br>805<br>806                      |                                   | http://www.sinopharm.com/s/1223-3769-39020.html (2021).  Reuters. Sinovac claims that the annual production capacity of COVID-19 vaccine will reach 2 billion doses by June.  https://cn.reuters.com/article/sinovac-biotech-covid-vaccine-0303-idCNKCS2AV0DL   |
| 803<br>804<br>805<br>806<br>807               | 25.                               | http://www.sinopharm.com/s/1223-3769-39020.html (2021).  Reuters. Sinovac claims that the annual production capacity of COVID-19 vaccine will reach 2 billion doses by June.  https://cn.reuters.com/article/sinovac-biotech-covid-vaccine-0303-idCNKCS2AV0DL (2021).   |
| 803<br>804<br>805<br>806<br>807<br>808        | 25.                               | http://www.sinopharm.com/s/1223-3769-39020.html (2021).  Reuters. Sinovac claims that the annual production capacity of COVID-19 vaccine will reach 2 billion doses by June.  https://cn.reuters.com/article/sinovac-biotech-covid-vaccine-0303-idCNKCS2AV0DL (2021).  Sinopharm. Chinese and foreign media enter the 1 billion-level COVID-19 vaccine  |
| 803<br>804<br>805<br>806<br>807<br>808<br>809 | 25.<br>26.                        | http://www.sinopharm.com/s/1223-3769-39020.html (2021).  Reuters. Sinovac claims that the annual production capacity of COVID-19 vaccine will reach 2 billion doses by June.  https://cn.reuters.com/article/sinovac-biotech-covid-vaccine-0303-idCNKCS2AV0DL (2021).  Sinopharm. Chinese and foreign media enter the 1 billion-level COVID-19 vaccine production base. <a href="http://www.sinopharm.com/s/1223-4126-39018.html">http://www.sinopharm.com/s/1223-4126-39018.html</a> (2021). |

| 813        | 28.        | Li, Q. et al. Early Transmission Dynamics in Wuhan, China, of Novel  |
|------------|------------|--|
| 814        |            | Coronavirus-Infected Pneumonia. N Engl J Med 382, 1199-1207 (2020).  |
| 815        | 29.        | Abbott, S., Hellewell, J., Munday, J., group, C.n.w. & Funk, S. The transmissibility of                              |
| 816        |            | novel Coronavirus in the early stages of the 2019-20 outbreak in Wuhan: Exploring                                    |
| 817        |            | initial point-source exposure sizes and durations using scenario analysis. Wellcome                                  |
| 818        |            | Open Res 5, 17 (2020).   |
| 819        | 30.        | Chinazzi, M. et al. The effect of travel restrictions on the spread of the 2019 novel                                |
| 820        |            | coronavirus (COVID-19) outbreak. <i>Science</i> <b>368</b> , 395-400 (2020).   |
| 821        | 31.        | Natsuko, I. et al. Report 3: Transmissibility of 2019-nCoV. Imperial College London.                                 |
| 822        |            | https://doi.org/10.25561/77148 (2020)  |
| 823        | 32.        | World Health Organization. Report of the WHO-China Joint Mission on Coronavirus                                      |
| 824        |            | Disease 2019 (COVID-19).   |
| 825        |            | https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coron                               |
| 826        |            | <u>avirus-disease-2019-(covid-19</u> ) (2021).   |
| 827        | 33.        | Hu, S. et al. Infectivity, susceptibility, and risk factors associated with SARS-CoV-2                               |
| 828        |            | transmission under intensive contact tracing in Hunan, China. Nature   |
| 829        |            | Communications 12, 1533 (2021).  |
|            |            |  |
| 830        | 34.        | Sun, K. et al. Transmission heterogeneities, kinetics, and controllability of  |
| 830<br>831 | 34.        | Sun, K. et al. Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2. <i>Science</i> , eabe2424. |
|            | 34.<br>35. |  |
| 831        |            | SARS-CoV-2. <i>Science</i> , eabe2424.   |

| 835 |     | in China. <i>Vaccines</i> <b>8</b> , 482 (2020).  |
|-----|-----|---|
| 836 | 37. | Wang, J. et al. The Changing Acceptance of COVID-19 Vaccination in Different  |
| 837 |     | Epidemic Phases in China: A Longitudinal Study. Vaccines (Basel) 9(2021).   |
| 838 | 38. | Shao, G., Ding, W., Yu, Y., Ma, H. & Zhijie, A. Willingness of parents to vaccinate   |
| 839 |     | family members with coronavirus disease 2019, influenza, and pneumococcal   |
| 840 |     | vaccines, Anyang city, May to June 2020. Chinese Journal of Vaccines and  |
| 841 |     | Immunization (2020).  |
| 842 | 39. | SINOVAC. Supply Vaccines to Eliminate Human Diseases.   |
| 843 |     | http://www.sinovac.com.cn/?optionid=468&auto_id=1877 (2021).  |
| 844 | 40. | CanSinoBIO. The application for conditional marketing of CansinoBio Coronavirus   |
| 845 |     | Vaccine ConvideciaTM was accepted by the National Medical Products  |
| 846 |     | Administration. <a href="http://www.cansinotech.com.cn/html/1///179/180/806.html">http://www.cansinotech.com.cn/html/1///179/180/806.html</a> (2021). |
| 847 | 41. | Beijing Institute of Biological Products Co., LTD. Products Instruction.  |
| 848 |     | https://www.bjbpi.com/?p=75 (2021).   |
| 849 | 42. | Palacios, R. et al. Efficacy and Safety of a COVID-19 Inactivated Vaccine in  |
| 850 |     | Healthcare Professionals in Brazil: The PROFISCOV Study. Preprint at SSRN   |
| 851 |     | https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3822780 (2021).   |
| 852 | 43. | Wuhan Institute of Biological Products Co., LTD. The interim analysis data of the   |
| 853 |     | COVID-19 inactivated vaccine phase III clinical trial of Sinopharm Wuhan Institute of   |
| 854 |     | Biological Products released. http://www.wibp.com.cn/Chs/Detail.aspx?ld=14669   |
| 855 |     | (2021).   |
| 856 | 44. | Centers for Disease Control and Prevention. About Variants of the Virus that Causes   |

| 857 |     | COVID-19. https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant.html            |
|-----|-----|--|
| 858 |     | (2021).  |
| 859 | 45. | Davies, N.G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage          |
| 860 |     | B.1.1.7 in England. <i>Science</i> , eabg3055 (2021).                                    |
| 861 | 46. | Stefanelli, P. et al. Co-circulation of SARS-CoV-2 variants B.1.1.7 and P.1. Preprint at |
| 862 |     | medRxiv https://www.medrxiv.org/content/10.1101/2021.04.06.21254923v1 (2021).            |
| 863 | 47. | Challen, R. et al. Risk of mortality in patients infected with SARS-CoV-2 variant of     |
| 864 |     | concern 202012/1: matched cohort study. <i>BMJ</i> <b>372</b> , n579 (2021).             |
| 865 | 48. | Davies, N.G. et al. Increased mortality in community-tested cases of SARS-CoV-2          |
| 866 |     | lineage B.1.1.7. <i>Nature</i> (2021).   |
| 867 | 49. | Meehan, M.T. et al. Age-targeted dose allocation can halve COVID-19 vaccine              |
| 868 |     | requirements. Preprint at medRxiv  |
| 869 |     | https://www.medrxiv.org/content/10.1101/2020.10.08.20208108v2 (2020).                    |
| 870 | 50. | Zhang, J. et al. The impact of relaxing interventions on human contact patterns and      |
| 871 |     | SARS-CoV-2 transmission in China. Science Advances 7, eabe2584 (2020).                   |
| 872 | 51. | Bubar, K.M. et al. Model-informed COVID-19 vaccine prioritization strategies by age      |
| 873 |     | and serostatus. <i>Science</i> <b>371</b> , 916-921 (2021).                              |
| 874 | 52. | Giordano, G. et al. Modeling vaccination rollouts, SARS-CoV-2 variants and the           |
| 875 |     | requirement for non-pharmaceutical interventions in Italy. Nat Med (2021).               |
| 876 | 53. | Li, Y. et al. The temporal association of introducing and lifting non-pharmaceutical     |
| 877 |     | interventions with the time-varying reproduction number (R) of SARS-CoV-2: a             |
| 878 |     | modelling study across 131 countries. Lancet Infect. Dis. 21, 193-202 (2021).            |

| 879 | 54. | Wibmer, C.K. et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African           |
|-----|-----|--|
| 880 |     | COVID-19 donor plasma. Preprint at <i>bioRxiv</i>  |
| 881 |     | http://biorxiv.org/content/early/2021/01/19/2021.01.18.427166.abstract (2021).           |
| 882 | 55. | Han, S. et al. Dynamic optimization of COVID-19 vaccine prioritization in the context of |
| 883 |     | limited supply. Preprint at Nature Portfolio   |
| 884 |     | https://www.researchsquare.com/article/rs-257573/v1 (2021).                              |
| 885 | 56. | Liu, Q.H. et al. Measurability of the epidemic reproduction number in data-driven        |
| 886 |     | contact networks. <i>Proc Natl Acad Sci U S A</i> <b>115</b> , 12680-12685 (2018).       |
| 887 | 57. | Population Division, Department of Economic and Social Affairs, United Nations.          |
| 888 |     | World Population Prospects 2019. https://population.un.org/wpp/ (2019).                  |
| 889 | 58. | Pan, A. et al. Association of Public Health Interventions With the Epidemiology of the   |
| 890 |     | COVID-19 Outbreak in Wuhan, China. <i>JAMA</i> <b>323</b> , 1915-1923 (2020).            |
| 891 | 59. | Li, Z. et al. Active case finding with case management: the key to tackling the          |
| 892 |     | COVID-19 pandemic. <i>Lancet</i> <b>396</b> , 63-70 (2020).                              |
| 893 | 60. | Xing, Y., Wong, G.W.K., Ni, W., Hu, X. & Xing, Q. Rapid Response to an Outbreak in       |
| 894 |     | Qingdao, China. <i>N Engl J Med</i> <b>383</b> , e129 (2020).                            |
| 895 | 61. | Xinhua net. The COVID-19 outbreak in Beijing.  |
| 896 |     | http://www.xinhuanet.com/politics/2020-06/19/c_1126135352.htm (2020).                    |
| 897 | 62. | The Central People's Government of the People's Republic of China. Report of H1N1        |
| 898 |     | pandemic influenza vaccination from Ministry of Health. http://www.gov.cn/gzdt           |
| 899 |     | (2020).  |
| 900 | 63. | Xiao, A. et al. Dynamic Profile of RT-PCR Findings from 301 COVID-19 Patients in         |

| 901 |     | Wuhan, China: A Descriptive Study. <i>Journal of Clinical Virology</i> <b>127</b> , 104346 (2020).  |
|-----|-----|---|
| 902 | 64. | Xia, S. et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine,                      |
| 903 |     | BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet                 |
| 904 |     | Infect Dis 21, 39-51 (2021).  |
| 905 | 65. | Callaway, E. COVID vaccine excitement builds as Moderna reports third positive                      |
| 906 |     | result. <i>Nature</i> <b>587</b> , 337-338 (2020).  |
| 907 | 66. | Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222)                      |
| 908 |     | against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil,             |
| 909 |     | South Africa, and the UK. <i>Lancet</i> <b>397</b> , 99-111 (2021).                                 |
| 910 | 67. | Polack, F.P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. $N$                  |
| 911 |     | Engl J Med <b>383</b> , 2603-2615 (2020).   |
| 912 | 68. | Yang, P. et al. Influenza vaccine effectiveness against medically-attended influenza                |
| 913 |     | illness during the 2012-2013 season in Beijing, China. <i>Vaccine</i> <b>32</b> , 5285-5289 (2014). |
| 914 |     |   |

915 **End notes** 916 Acknowledgments 917 The study was supported by grants from the National Science Fund for Distinguished 918 Young Scholars (No. 81525023), Key Emergency Project of Shanghai Science and 919 Technology Committee (No 20411950100), European Union Grant 874850 MOOD 920 (MOOD 000). 921 922 **Author Contributions** 923 H.Y. conceived the study. H.Y., S.M., and M.A. designed and supervised the study. 924 J.Y., J. Z., J.C., W.W., Q.W., W.Z., Z.Z, K.D., and G.Z. participated in data collection. 925 V.M., G.G., P.P., and F.T. developed the model. V.M., J.Y., and X.D. analyzed the 926 model outputs and prepared the tables and figures. J.Y. prepared the first draft of the 927 manuscript. H.Y., V.M., and M.A. commented on the data and its interpretation, 928 revised the content critically. All authors contributed to review and revision and 929 approved the final manuscript as submitted and agree to be accountable for all aspects 930 of the work. 931 932 **Declaration of interests** 933 H.Y. has received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang 934 HEC Changjiang Pharmaceutical Company, and Shanghai Roche Pharmaceutical 935 Company. M.A. has received research funding from Seqirus. None of those research 936 funding is related to COVID-19. All other authors report no competing interests.

937 938 **Disclaimer** 939 This article does not necessarily represent the views of the NIH or the US 940 government. 941 942 **Additional information** 943 **Supplementary Information** is available for this paper. 944 Correspondence and requests for materials should be addressed to M.A., and H.Y. 945 Peer review information. 946 information **Reprints** and permissions is available at 947 http://www.nature.com/reprints.